Director, Cardiac Catheterization Laboratory

Interventional Director, Structural Heart Program for Mount Sinai Health System

Director, Interventional Cardiology Fellowship Program

Zena and Michael A. Weiner Professor of Medicine

Annapoorna S. Kini, MD, is internationally acclaimed for her special expertise in performing complex coronary interventions, especially in chronic total occlusion for patients with advanced coronary artery disease, high-risk interventional cases, and alcohol septal ablation for the treatment of obstructive hypertrophic cardiomyopathy. Dr. Kini performs more than 1,000 coronary interventions annually, the highest number by a female interventionist in the United States, with an extremely low complication rate of less than 0.3 percent.

Dr. Kini has been the principal or co-investigator in numerous randomized clinical trials. She has extensive experience with mitral and aortic balloon valvuloplasty. She has been among the first interventional cardiologists in the country to use the transcutaneous aortic valve implantation procedure to treat inoperable patients with critical aortic stenosis. She has also made history by performing the first live case performed entirely by women during the CRT meeting on March 5, 2018.

Dr. Kini performs more than 1,000 coronary interventions annually, the highest number by a female interventionist in the United States, with an extremely low complication rate of less than 0.3 percent; an official report from The New York State Department of Health recognized Dr. Kini as the safest operator among 350 other physicians in the state of New York numerous times (2004-2016). She received the 2011 Dean’s Award for Excellence in Clinical Medicine at The Mount Sinai Hospital. She also received the Physician of the Year award in 2014 from The Mount Sinai Hospital nurses. She received the Excellence in Medicine Award from the National Association of Physicians of India (AAPI) in July 2016. In May 2017, she received the prestigious Ellis Island Medal of Honor, the highest award given to any immigrant civilian, and in 2018 she received the American Heart Association’s Heart of Gold Award. Dr. Kini received the “Rock Star of Science” award from the American Heart Association. She is a member of the Royal College of Physicians of London and a Fellow of the American College of Cardiology.

The recent YELLOW III study, which was presented at ACC 2023 as a LBCT, was an ambitious translational combination of multimodality imaging with clinically relevant cellular biology and comprehensive transcriptomics to better assess the effect of evolocumab on coronary plaque morphology. In the digital field, Dr. Kini has led the development of eight free educational applications. She has also created a mobile app-based chair yoga program for her recent SLYM II trial. She is developing a patient experience and education platform called TAVRbot for structural heart patients. Her recent STEMIcathAID Piloted at Mount Sinai Queens has been working to reduce the device time to reperfusion on vulnerable heart attack patients since July of 2021. Dr. Kini is an excellent teacher dedicated to teaching cardiology and interventional fellows. In fact, the 2012 batch of Mount Sinai interventional fellows created a teaching award in her name, “The Annapoorna S. Kini Fellows’ Choice Award” for excellence in teaching.

Her achievements are not limited to serving as the Director of the Annual Live Symposium of Complex Coronary Cases at The Mount Sinai Hospital, one of the most attended and respected meetings in the field of interventional cardiology in the country. She is also the Director of a monthly webcast program, CCC Live Cases (www.ccclivecases.org), which started in 2009 and has an audience of more than 25,000 in 179 countries.